Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics.
- Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics.
- “Conventional bulk methods for detecting chromosomal rearrangements are limited in scale and accuracy,” said Vanee Pho, PhD, Senior Director of Product Management, Cell and Gene Therapy at Mission Bio.
- “Through our single-cell Tapestri Platform, our latest translocation analysis provides our customers with a comprehensive picture of gene edits and unwanted chromosomal aberrations at single-cell resolution — enabling critical safety assessment of these innovative therapies.
- “With Mission Bio’s translocation approach, we can profile off-target activity and genome-editing efficiency more robustly and with unparalleled precision.